Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $14.37, but opened at $14.00. Day One Biopharmaceuticals shares last traded at $14.78, with a volume of 923,241 shares changing hands.
Analysts Set New Price Targets
A number of brokerages have recently commented on DAWN. Needham & Company LLC lowered their price objective on Day One Biopharmaceuticals from $48.00 to $44.00 and set a “buy” rating for the company in a research report on Wednesday, April 5th. Bank of America downgraded Day One Biopharmaceuticals from a “buy” rating to an “underperform” rating in a research report on Tuesday, April 25th. Finally, HC Wainwright lifted their target price on Day One Biopharmaceuticals from $45.00 to $50.00 in a report on Monday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $44.29.
Day One Biopharmaceuticals Stock Performance
The stock has a 50 day simple moving average of $13.13 and a 200 day simple moving average of $17.66.
Insider Buying and Selling
In related news, CEO Jeremy Bender sold 3,104 shares of the business’s stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $13.12, for a total value of $40,724.48. Following the transaction, the chief executive officer now owns 1,179,484 shares in the company, valued at $15,474,830.08. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last 90 days, insiders have sold 5,980 shares of company stock worth $81,997. 8.80% of the stock is currently owned by corporate insiders.
Institutional Trading of Day One Biopharmaceuticals
Hedge funds and other institutional investors have recently bought and sold shares of the company. Strs Ohio bought a new stake in Day One Biopharmaceuticals in the first quarter valued at about $30,000. Quintet Private Bank Europe S.A. bought a new position in shares of Day One Biopharmaceuticals during the first quarter valued at approximately $31,000. Quantbot Technologies LP bought a new position in shares of Day One Biopharmaceuticals during the second quarter valued at approximately $51,000. Amalgamated Bank grew its holdings in shares of Day One Biopharmaceuticals by 21.0% during the third quarter. Amalgamated Bank now owns 3,577 shares of the company’s stock valued at $72,000 after purchasing an additional 620 shares during the last quarter. Finally, UBS Group AG bought a new position in shares of Day One Biopharmaceuticals during the second quarter valued at approximately $69,000. 86.08% of the stock is owned by institutional investors.
Day One Biopharmaceuticals Company Profile
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
Read More
- Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
- Hooker Furnishings Discount To Book, A Value Play?
- REV Group Shifts Into High Gear: Double-Digit Upside Ahead
- Can Kirkland’s Cycle Pick Up Again? Earnings May Have An Answer
- Don’t Bet On A Rally In Stitch Fix, Invest In The Future
- 2 Dow Stocks Trading Less Than 10x Earnings are Blue Chip Values
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
